Older adults with type 2 diabetes (T2D) are at an increased risk of cardiovascular disease (CVD) compared with those without T2D.1 Although professional societies recommend the 2 classes of glucose-lowering agents, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), for their cardioprotective effects,2,3 adoption of these guidelines in routine care remains a challenge because evidence suggests that their cardiovascular benefits might not be uniform across patient subgroups. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.